Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Freegold Intersects 3.62 g/t Au over 42m and 1.23 g/t Au over 170.7m (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc.
Bullboard Posts
User Avatar Image
(1118)
•••
Comment by Hempdocon May 06, 2020 11:24pm
144 Views
Post# 30996044

RE:RE:FDA priority

RE:RE:FDA priority
PeerReviewed wrote: Interesting one Harpos.

It's related to UUTUC.

UTUC is diagnosed in an estimated 6,000 to 7,000 patients per year and typically requires multiple surgeries to treat, including kidney removal, UroGen said in a statement about the approval. Most patients are older than 70, making surgery particularly risky.

Jelmyto, by contrast, is applied to the urinary tract using a catheter and is the first non-surgical treatment approved to treat the disease.


Jelmyto was approved based on a phase 3 study in which patients received the drug once a week for six weeks. Following the treatment, 58% of participants had a complete response, and one year later, 46% of those patients were still responding.

Source: With Urogen's Jelmyto nod, Big Pharma vet Liz Barrett preps for a virtual launch
 



 

Not bad %s, but not too good either...27% CR at 1 yr.  These relatively low %s coming out for all of the new urothelial cancer treatments are simply setting the stage for the main act....our shining moment is coming soon.

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities